AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03205917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)
Description: 3/1 (6/2 if DLT)
Study NCT00865449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, given daily for 6 months to Peritoneal Dialysis Patients
Study NCT04225260 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin neuromodulator
Description: A dose of QM1114-DP will be injected in the GL area and in the LCL area.
Study NCT03205917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)
Description: 3 (max 9)
Study NCT03205917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400 + PGT121 (MTD IV)
Description: 3 (max 9)
Study NCT03744676 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lisocabtagene maraleucel
Description: lisocabtagene maraleucel will be administered as single dose intravenous (IV) injection
Study NCT00927823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04691502
Description: Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.
Study NCT01149681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APLIDIN (plitidepsin)
Description: Aplidin® (plitidepsin) lyophilized powder and solvent for concentrate for solution for infusion. (2 mg plitidepsin vial and 4 ml ampoule).~Plitidepsin will be administered at 5 mg/m2 intravenously diluted to a total volume of 250 ml in 0.9% saline or 5% dextrose solution on Day 1 and 15 every four weeks for a maximum period of 6 cycles.
Study NCT00699244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral placement of local anesthesia
Description: Peripheral placement of local anesthesia
Study NCT00699244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central placement of local anesthesia
Description: Central placement of local anesthesia
Study NCT02232178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 100mg Xaracoll implants
Study NCT03480685 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IVUS and OCT Imaging
Description: Use of an imaging catheter
Study NCT04612530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (IRE)
Description: Irreversible electroporation (IRE) is a local ablative technique that utilizes electrical pulses to destroy tumor tissue
Study NCT04612530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.
Study NCT04612530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.
Study NCT04612530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toll-Like Receptor 9
Description: Toll-Like Receptor 9 (CpG) is an oligodeoxynucleotide that stimulates dendritic cells to release IFN type I, activating natural killer and infiltrating T cells. This creates a more pro-immunogenic tumor environment.
Study NCT00873834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized
Study NCT03095339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational package
Description: The educational package was offered to 30 villages post randomization. The field team completed the SARAR PHAST with community members for 2-3 days in each intervention village. The movie was projected every night for 2-3 days in each intervention village.
Study NCT02232178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 100mg Xaracoll implants
Study NCT02232178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150mg Bupivacaine HCl injection
Study NCT04037735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATTUNE S+ Knee Prosthesis by DePuy
Description: Total Knee Replacement (TKR) Surgery with ATTUNE S+ Knee Prosthesis by DePuy
Study NCT04037735 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFC Sigma Knee Prosthesis by DePuy
Description: Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
Study NCT00957086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotuzumab
Description: Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
Study NCT00957086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
Study NCT03357341 — intervention group
Intervention type: DEVICE
Intervention: Mobile spirometer
Description: Mobile spirometer will be used to measure FEV1 values weekly.
Study NCT03357341 — intervention group
Intervention type: DEVICE
Intervention: Device sensor
Description: Sensors will be attached to rescue and maintenance inhalers to measure use of rescue medication and maintenance therapy.
Study NCT03357341 — intervention group
Intervention type: DRUG
Intervention: Salbutamol
Description: Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
Study NCT03357341 — intervention group
Intervention type: DEVICE
Intervention: Activity monitor
Description: Subjects will be required to wear activity monitors daily to record their physical activity.
Study NCT00873834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
Study NCT00808717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 10 mg vs. 80 mg before intervention
Study NCT03762122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib
Description: Rogaratinib (BAY 1163877; Bayer) is an oral pan-kinase inhibitor, which selectively inhibits FGFR1, FGFR2, FGFR3, and FGFR4.
Study NCT00114101 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSCT
Study NCT00114101 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSCT
Study NCT00114101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00114101 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00114101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02210546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Study NCT02210546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mammography (Mx) + ultrasonography (US)
Study NCT01570088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: One roll/bun per day fortified with 400 µg of folic acid
Study NCT01570088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-5-MTHF
Description: One roll/bun per day fortified with 452 µg of L-5-MTHF
Study NCT01570088 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains no folic acids
Study NCT02802943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine
Description: Individualized multi-peptide cocktail consisting of 300 μg each of 5 HLA class I and 4 HLA class II restricted peptides. The peptides for each individual patient will be selected from a warehouse consisting of 30 different peptides restricted by the 6 most common HLA class I allotypes (A\*01, A\*02, A\*03, A\*24, B\*07, B\*08) and 4 HLA class II peptides. Peptides will be administered subcutaneously. Vaccination will take place on d1, d4, d8, d15, d22 followed by vaccinations every 4 weeks for 1 year. The peptide warehouse is selected based on our data on the non-mutant HLA-presented antigenome of CLL identified as frequently presented CLL-associated T cell epitopes with a high potential for broad clinical application.
Study NCT02802943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: All patients will receive imiquimod (Aldara®) as local adjuvant, applied topically at the side of vaccination 18h to 24h prior to the vaccination.
Study NCT02322346 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group S
Description: Peritonsillar infiltration with saline Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour.
Study NCT02322346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group LL
Description: Peritonsillar infiltration with low-dose of levobupivacaine 0.25%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour.
Study NCT02322346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group HL
Description: Peritonsillar infiltration with high dose of levobupivacaine 0.5%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour.
Study NCT03357341 — intervention group
Intervention type: OTHER
Intervention: electronic diary card
Description: Electronic diary card will be completed daily by subjects in COPD cohort.
Study NCT03357341 — intervention group
Intervention type: OTHER
Intervention: CAT
Description: Subjects will be required to complete CAT monthly.
Study NCT03357341 — intervention group
Intervention type: OTHER
Intervention: ACT
Description: Subjects will be required to complete ACT monthly.
Study NCT01903174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroForm Breast Tissue Expander
Description: Breast Tissue Expander using a remote control to fill the expander with Carbon Dioxide
Study NCT01604408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: Administered SC
Study NCT02114840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pronator quadratus preservation after volar plate fixation in wrist fractures
Description: Pronator quadratus preservation after volar plate fixation in wrist fractures
Study NCT02114840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pronator quadratus repair after volar plate fixation in wrist fractures
Description: Pronator quadratus repair after volar plate fixation in wrist fractures
Study NCT02114840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pronator quadratus nonrepair after volar plate fixation in wrist fractures
Description: Pronator quadratus nonrepair after volar plate fixation in wrist fractures
Study NCT00849979 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire
Description: Day 1 MDASI-GI Questionnaire
Study NCT00849979 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Description: Open-ended, audiotaped interviews
Study NCT00086957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Cycle 1 loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for subsequent cycles.
Study NCT00086957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 every three weeks, or 60 mg/m2 every three weeks depending on study findings
Study NCT00086957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: 250 mg daily or 250 mg daily on days 2 through 14 depending on study findings
Study NCT01300897 — intervention group
Intervention type: PROCEDURE
Intervention: Cortical Evoked Potentials
Description: A probe with 2 ring electrodes is placed in the anorectum. A small amount of electric current is passed separately through the anal and rectal electrodes.. The cortical evoked potentials from the anal and rectal sites are measured.
Study NCT01300897 — intervention group
Intervention type: PROCEDURE
Intervention: Transcranial motor evoked potentials
Description: A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the scalp at the anorectal site on each side, and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
Study NCT01300897 — intervention group
Intervention type: PROCEDURE
Intervention: Translumbosacral motor evoked potentials
Description: A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the back at the lumbar plexus and sacral plexus levels and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
Study NCT01403740 — intervention group
Intervention type: DRUG
Intervention: rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin
Description: According to local clinical standards
Study NCT04212338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Before intravitreal injection music intervention
Description: The patients in the Before-IVTI group listened to music for a period of 15 minutes 30 minutes before the injection.
Study NCT04212338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: during intravitreal injection music intervention
Description: The patients in the During-IVTI group listened to music during the injection (approximately 5 minutes).
Study NCT02081339 — intervention group
Intervention type: DRUG
Intervention: ranibizumab, aflibercept, pegaptanib, verteporphin
Study NCT01542476 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
Study NCT02422953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Soya Blend (WSB)
Description: A monthly ration of 5 Kg of Wheat Soya Blend (WSB) will be given to pregnant women every month during pregnancy and lactating mothers for six months after giving birth
Study NCT02422953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wawa Mum
Description: Children 6-23 months of age will receive a daily ration of 50 gram of Wawa Mum during study period
Study NCT02422953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Powders (MNP)
Description: Children 24-59 months of age will receive a sachet of Micronutrient Powders (MNP) in alternate days
Study NCT02422953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change and preventive health massages
Description: Behavior change and preventive health massages will be delivered by lady health workers (LHWs) during monthly visits and in group meetings
Study NCT00540436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325760A
Description: Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
Study NCT04068558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNI-NAVA/sNIPPV
Description: Ventilation of the child in NIV-NAVA for 2 hours then ventilation of the child in sNIPPV for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
Study NCT04068558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sNIPPV/VNI-NAVA
Description: Ventilation of the child in sNIPPV for 2 hours then ventilation of the child in NIV-NAVA for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
Study NCT01526018 — intervention group
Intervention type: BEHAVIORAL
Intervention: Podee bottle
Description: Infants will acclimate to the Podee bottle over the course of several weeks. All infants will consume meals from the Podee and their usual bottles.
Study NCT00808717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10 mg vs. 80 mg before intervention
Study NCT04152369 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anti-microbial prophylaxis for an endourological procedure or ESWL
Description: anti-microbial prophylaxis according to urine culture results
Study NCT02805309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercises will target balance, flexibility, strength, and endurance (source: https://go4life.nia.nih.gov/). Home visits will take place twice a week for week 1 and 2; once a week for week 3 and 4; every other week for week for week 5 through week 8. Participants are instructed to do prescribed exercises for 30 minutes daily. The duration of this intervention is about 40 mins.
Study NCT02805309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral interventions
Description: The following cognitive-behavioral strategies will be employed: 1) enhance positive beliefs about exercise through discussion of benefits of exercise; 2) discussion of barriers to exercise; 3) individualized goal setting and self-monitoring progress using exercise calendar; 4) develop a detailed exercise plan on how, what, when, and where to conduct exercise; 5) $10 rewards for exercising ≥30 mins per day for ≥5 of 7 days. The duration of this intervention is about 20 mins.
Study NCT02805309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control education program
Description: A health care professional will call the participant weekly for a period of 8 weeks to teach general tips about exercise and diet (source: https://go4life.nia.nih.gov/). No recommendations for a specific exercise program will be made, except for walking 30 minutes daily or as tolerated. Each telephone session will cover 4 exercise tips and 4 healthy eating tips. The duration of the intervention is about 30 minutes.
Study NCT01618630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EAA Supplementation + Exercise Training
Description: Amino acids in drinks between meals for exercise training period.
Study NCT01618630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Exercise Training
Description: Placebo supplementation as drinks in between meals for exercise training period.
Study NCT04125615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protected Time Intervention
Description: Participants were assigned two hours of protected, non-clinical time by the chief resident of the service. Chief residents were instructed to assign this time when clinical learning opportunities were lowest. Each participant acted as their own control and was on the intervention phase of the study for the first or last 6 weeks of a quarterly rotation. Residents were concurrently assigned to the same phase of the study (intervention versus control). Participants were not specifically limited in what they could do during their non-clinical time, but they were encouraged to use this time in a way they felt would decrease their own personal burnout and increase their well-being, whether this be performing work-related administrative duties previously done on personal time or fulfilling obligations that are integral to personal health and well-being that can only be completed during normal business hours.
Study NCT00875888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous venovenous hemodialysis
Description: dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.